Tuesday featured heavy selling reversing Monday’s light volume rally. Sell day’s volume continues to overwhelm previous light volume rallies. The conclusion is “distribution” or “getting out” of markets is pervasive. Another way of putting this is perma-bulls are wasting their
September 22, 2015
Podcast: Play in new window | Play in new window (Duration: 13:17 — 6.1MB) DOW – 179 = 16,330 SPX – 24 = 1942 NAS – 72 = 4756 10 YR YLD – .09 = 2.12% OIL – .85 =
In our prior post (Bear Market Watch 2015-09-20), we presented a monthly indicator that has done a pretty good job of identifying top of market exit points and post-bottom re-entry points for the S&P 500. It combines 4 technical indicators into
I will give the Fed this much. Although they have historically been lousy forecasters, I think that at least a few of them may be dovish at this moment not just because they are always dovish, but because they believe
The Fed Has Tried Both Sides Last Thursday, the Federal Reserve did not raise interest rates. While the “no rate increase” scenario is typically favorable for stocks, the S&P 500 was unable to hold onto the post Fed statement gains.
Today we saw another stock market decline and yet another shift further away from rate hikes this year. I put this table together from CME FedWatch data. FOMC Meeting Date No Hike Probability on Sep 22 No Hike Probability on
It is no secret that with the rest of the US economy, and especially housing, sputtering the one bright spot for US production and manufacturing has been the automotive sector. Whether the recent strength has been a function of money-losing
The economy is a two-headed monster. One head is the trade in real goods and real services. The other head is the financialized traffic in swindles and frauds that surrounds banking. There is some deception and overlap about which is
The social media world can be a valuable tool for investors. Whether it be breaking news or stock picks, there are thousands of accounts on Twitter (TWTR – Analyst Report) that help us stay informed and make real-time investment decisions. The real
Shares of Heron Therapeutics (HRTX) were up 22% in after hours trade after announcing positive phase 2 results for post-operative pain. These positive results stem from a phase 2 trial with the company’s HTX-011 drug formulation. The company uses its
